Jul 10, 2025 7:00am EDT Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025
Jul 9, 2025 4:01pm EDT Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
Jul 7, 2025 7:00am EDT Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
Jul 2, 2025 7:00am EDT Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models
Jun 30, 2025 7:00am EDT Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Jun 16, 2025 7:00am EDT Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025
Jun 13, 2025 7:00am EDT Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors
Jun 10, 2025 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention
Jun 5, 2025 7:00am EDT Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025
May 22, 2025 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
